302 related articles for article (PubMed ID: 33995990)
1. Busulfan plus melphalan
Park S; Shin DY; Hong J; Kim I; Koh Y; Byun JM; Yoon SS
Ther Adv Hematol; 2021; 12():20406207211012985. PubMed ID: 33995990
[TBL] [Abstract][Full Text] [Related]
2. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
[TBL] [Abstract][Full Text] [Related]
3. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
Byun JM; Lee J; Shin SJ; Kang M; Yoon SS; Koh Y
Blood Res; 2018 Jun; 53(2):105-109. PubMed ID: 29963515
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m
Gao F; Lin MS; You JS; Zhang MY; Cheng L; Lin K; Zhao P; Chen QY
Cancer Cell Int; 2021 Nov; 21(1):601. PubMed ID: 34758834
[TBL] [Abstract][Full Text] [Related]
5. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Czerw T; Pabst T; Blaise D; Dumas PY; Nemet D; Arcese W; Trisolini SM; Wu D; Huynh A; Zuckerman T; Meijer E; Cagirgan S; Cornelissen J; Houhou M; Polge E; Mohty M; Nagler A
Cancer; 2017 Mar; 123(5):824-831. PubMed ID: 27906458
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
10. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
[TBL] [Abstract][Full Text] [Related]
11. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
12. Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment.
Zhou S; Zhai Y; Yan L; Shi X; Shang J; Wu D; Fu C; Jin S
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834886
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P
Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404
[TBL] [Abstract][Full Text] [Related]
14. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.
Gorin NC; Labopin M; Blaise D; Dumas PY; Pabst T; Trisolini SM; Arcese W; Houhou M; Mohty M; Nagler A
Am J Hematol; 2018 Jul; 93(7):859-866. PubMed ID: 29644709
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
18. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma.
Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B
Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Nieto Y; Yang Z; Valdez BC; Kundu S; Bashir Q; Ramdial J; Srour S; Qazilbash M
Am J Hematol; 2024 Feb; 99(2):245-253. PubMed ID: 38100199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
